Proton Craniospinal Irradiation for Leptomeningeal Metastasis

(BRAVO-LM Trial)

This trial aims to determine if a new radiation treatment, BRAVO pCSI (BRain-AVOidant Proton Craniospinal Irradiation), is effective for individuals with leptomeningeal metastases, where cancer spreads to the membranes around the brain and spinal cord. The trial consists of two parts: one group will receive the radiation treatment, while the other group will not receive treatment but will undergo the same assessments. This trial targets adults with breast cancer or non-small cell lung cancer who have cancer spread to the membranes around their brain or spine, without extensive disease or serious brain damage. As an unphased trial, it offers patients the chance to contribute to groundbreaking research that could lead to new treatment options.

Research has shown that BRain-AVOidant proton craniospinal irradiation (BRAVO pCSI) is generally safe for patients. One study found that this treatment is feasible even for those who previously underwent radiation therapy, suggesting good tolerance. Although specific side effects are not detailed, evidence indicates no major safety concerns. Furthermore, the use of proton therapy in other approved cancer treatments adds confidence in its safety for patients considering this trial.¹²³⁴⁵

Proton craniospinal irradiation, specifically the BRain-AVOidant Proton Craniospinal Irradiation (BRAVO pCSI), is unique because it targets leptomeningeal metastasis while sparing the brain from unnecessary radiation. This is different from conventional treatments, which often expose the whole brain to radiation, potentially leading to significant side effects. Researchers are excited about BRAVO pCSI because it offers a more focused approach, which could minimize damage to healthy brain tissue and improve patients' quality of life. Additionally, using proton therapy allows for precise delivery of radiation, potentially enhancing treatment effectiveness and reducing collateral damage compared to standard radiation therapies.

Research has shown that BRain-AVOidant proton craniospinal irradiation (BRAVO pCSI), which participants in this trial may receive, might effectively treat leptomeningeal metastases, a condition where cancer spreads to the protective layers around the brain and spinal cord. Studies indicate that proton craniospinal irradiation has improved survival rates for patients with this condition. Specifically, patients who received proton therapy lived a median of 11.3 months, compared to 4.9 months with other treatments. This method aims to protect healthy brain areas, potentially reducing side effects while effectively targeting the cancer. Early results suggest that patients tolerate this approach well, experiencing fewer severe issues during treatment.²³⁴⁵⁶